PAREXEL APPOINTS MICHAEL J. MCKELVEY, Ph.D., TO LEAD WORLDWIDE DATA MANAGEMENT BUSINESS
BOSTON, MA, February 12, 2001 — PAREXEL International Corporation (Nasdaq: PRXL) today announced that Michael J. McKelvey, Ph.D., has joined PAREXEL as Senior Vice President, Worldwide Data Management. In this capacity, Dr. McKelvey will lead PAREXEL’s global data management business, which is one of the largest in the CRO industry, with over 750 employees worldwide. PAREXEL provides a complete range of data management services, leveraged with industry leading information technologies.
Dr. McKelvey brings to PAREXEL over 25 years of general management experience in various information technology companies. Most recently, he was Executive Vice President of the ICF Consulting Group and President of ICF Information Technology, Inc. At ICF, Dr. McKelvey was responsible for developing innovative e-business products and services for global companies and organizations in the environmental and energy industries. Dr. McKelvey joined ICF from DRI/McGraw-Hill, where he held several senior management positions and headed its Information Management Practice. Prior to DRI/McGraw-Hill, Dr. McKelvey directed economic forecasting for the Bureau of Economic Analysis, U.S. Department of Commerce. Dr. McKelvey received his B.A. from Williams College and a M.A. and Ph.D. from the Wharton School, University of Pennsylvania.
“We are extremely pleased to add Dr. McKelvey to our Clinical Research Services (CRS) organization. His expertise and leadership in developing and implementing IT strategies will be a strong addition to PAREXEL’s data management business and help us to maintain our industry leadership,” said Barry Philpott, President of PAREXEL’s CRS Business Unit.
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its newest subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 47 locations throughout 29 countries around the world, and has approximately 4,350 employees.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended September 30, 2000, as amended by a Form 10-Q/A filed with the Securities and Exchange Commission on January 5, 2001.